Resultados globales: 3 registros encontrados en 0.02 segundos.
Artículos, Encontrados 3 registros
Artículos Encontrados 3 registros  
1.
16 p, 3.8 MB Genetic and phenotypic attributes of splenic marginal zone lymphoma / Bonfiglio, Ferdinando (Institute of Oncology Research, Bellinzona, Switzerland) ; Bruscaggin, Alessio (Institute of Oncology Research, Bellinzona, Switzerland) ; Guidetti, Francesca (Institute of Oncology Research, Bellinzona, Switzerland) ; Terzi di Bergamo, Lodovico (Institute of Oncology Research, Bellinzona, Switzerland) ; Faderl, Martin (Institute of Oncology Research, Bellinzona, Switzerland) ; Spina, Valeria (Institute of Oncology Research, Bellinzona, Switzerland) ; Condoluci, Adalgisa (Institute of Oncology Research, Bellinzona, Switzerland) ; Bonomini, Luisella (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ; Forestieri, Gabriela (Institute of Oncology Research, Bellinzona, Switzerland) ; Koch, Ricardo (Institute of Oncology Research, Bellinzona, Switzerland) ; Piffaretti, Deborah (Institute of Oncology Research, Bellinzona, Switzerland) ; Pini, Katia (Institute of Oncology Research, Bellinzona, Switzerland) ; Pirosa, Maria Cristina (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Cittone, Micol Giulia (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Arribas, Alberto (Lymphoma Genomics, Institute of Oncology Research, Bellinzona, Switzerland) ; Lucioni, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Pavia, Italy) ; Ghilardi, Guido (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.) ; Wu, Wei (Institute of Oncology Research, Bellinzona, Switzerland) ; Arcaini, Luca (University of Pavia, Pavia, Italy.) ; Baptista, Maria Joao (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Bastidas-Mora, Gabriela (Hospital Clínic i Provincial de Barcelona) ; Bea, Sílvia (Hospital Clínic i Provincial de Barcelona) ; Boldorini, Renzo (University of Eastern Piedmont, Novara, Italy) ; Broccoli, Alessandro (IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia Seràgnoli, Bologna, Italy.) ; Buehler, Marco Matteo (University Hospital Zurich, Switzerland) ; Canzonieri, Vincenzo (Pathology Unit, CRO Aviano National Cancer Institute, Aviano, Italy) ; Cascione, Luciano (Institute of Oncology Research, Bellinzona, Switzerland) ; Ceriani, Luca (Clinic of Nuclear Medicine and PET-CT Centre, Imaging Institute of Southern Switzerland, Bellinzona, Switzerland) ; Cogliatti, Sergio (Institute of Pathology, Kantonsspital St Gallen, St Gallen, Switzerland) ; Corradini, Paolo (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan, Italy) ; Derenzini, Enrico (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ; Devizzi, Liliana (Division of Hematology, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ; Dietrich, Sascha (University Hospital Heidelberg, Germany) ; Elia, Angela Rita (Institute of Oncology Research, Bellinzona, Switzerland) ; Facchetti, Fabio (Pathology Unit, Spedali Civili, Brescia, Italy) ; Gaidano, Gianluca (University of Eastern Piedmont, Novara, Italy) ; Garcia, Juan Fernando (MD Anderson Cancer Center, Madrid) ; Gerber, Bernhard (Division of Hematology, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Ghia, Paolo (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ; Gomes da Silva, Maria (Instituto Português de Oncologia de Lisboa, Portugal) ; Gritti, Giuseppe (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ; Guidetti, Anna (Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Italy) ; Hitz, Felicitas (Kantonsspital St Gallen, St Gallen, Switzerland) ; Inghirami, Giorgio (Weill Cornell Medical College, New York) ; Ladetto, Marco (Azienda Ospedaliera SS Antonio e Biagio, Alessandria, Italy) ; Lopez-Guillermo, Armando (Hospital Clínic i Provincial de Barcelona) ; Lucchini, Elisa (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ; Maiorana, Antonino (Universitá degli Studi di Modena e Reggio Emilia, Modena, Italy) ; Marasca, Roberto (University of Modena and Reggio Emilia, Modena, Italy) ; Matutes, Estella (Hospital Clínic i Provincial de Barcelona) ; Meignin, Veronique (Saint Louis Hospital, Paris, France) ; Merli, Michele (University of Insubria and ASST Sette Laghi, Ospedale di Circolo of Varese, Varese, Italy) ; Moccia, Alden (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Mollejo, Manuela (Hospital Virgen de la Salud (Toledo)) ; Montalban, Carlos (MD Anderson Cancer Center, Madrid) ; Novak, Urban (University of Bern, Bern, Switzerland) ; Oscier, David Graham (University Hospitals Dorset, Bournemouth, United Kingdom) ; Passamonti, Francesco (University of Insubria) ; Piazza, Francesco (Ospedale Universitario di Padova, Italy) ; Pizzolitto, Stefano (General Hospital S Maria della Misericordia, Udine, Italy) ; Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy) ; Sabattini, Elena (University of Bologna, Italy) ; Salles, Gilles (Université de Lyon, France) ; Santambrogio, Elisa (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ; Scarfò, Lydia (IRCCS Ospedale San Raffaele and Università Vita-Salute San Raffaele, Milan, Italy) ; Stathis, Anastasios (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Stüssi, Georg (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Geyer, Julia T. (Weill Cornell Medical College, New York) ; Tapia, G. (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ; Tarella, Corrado (European Institute of Oncology (IEO) IRCCS, Milan, Italy) ; Thieblemont, Catherine (Université de Paris, France) ; Tousseyn, Thomas (University Hospitals Leuven, Belgium) ; Tucci, Alessandra (Spedali Civili, Brescia, Italy.) ; Vanini, Giorgio (University of Bern, Switzerland) ; Visco, Carlo (University of Verona, Italy) ; Vitolo, Umberto (Candiolo Cancer Institute (FPO-IRCCS), Candiolo, Turin, Italy) ; Walewska, Renata (University Hospitals Dorset, Bournemouth, United Kingdom) ; Zaja, Francesco (Azienda Sanitaria Universitaria Giuliano Isontina, Trieste, Italy) ; Zenz, Thorsten (University Hospital Zurich, Switzerland) ; Zinzani, Pier Luigi (Università di Bologna, Italy) ; Khiabanian, Hossein (Rutgers University, New Brunswick) ; Calcinotto, Arianna (Institute of Oncology Research, Bellinzona, Switzerland) ; Bertoni, Francesco (Institute of Oncology Research, Bellinzona, Switzerland) ; Bhagat, Govind (Columbia University, New York, USA) ; Campo, Elias (Hospital Clínic i Provincial de Barcelona) ; de Leval, Laurence (Institut Universitaire de Pathologie, Lausanne, Switzerland) ; Dirnhofer, Stefan (University Hospital Basel (Basilea, Suïssa)) ; Pileri, Stefano A. (European Institute of Oncology IRCCS, Milan, Italy) ; Piris, Miguel Angel (Centro de Investigación Biomédica en Red de Cáncer (CIBERONC) Madrid) ; Traverse-Glehen, Alexandra (Centre Hospitalier Lyon Sud, Lyon, France) ; Tzankov, Alexander (University Hospital Basel (Basilea, Suïssa)) ; Paulli, Marco (Fondazione IRCCS Policlinico San Matteo and Università degli Studi di Pavia, Italy) ; Ponzoni, Maurilio (Ateneo Vita-Salute San Raffaele University and Pathology Unit San Raffaele Scientific Institute, Milan, Italy) ; Mazzucchelli, Luca (antonal Institute of Pathology, Locarno, Switzerland) ; Cavalli, Franco (Institute of Oncology Research, Bellinzona, Switzerland; and.) ; Zucca, Emanuele (International Extranodal Lymphoma Study Group, Bellinzona, Switzerland) ; Rossi, Davide (Oncology Institute of Southern Switzerland, Bellinzona, Switzerland) ; Universitat Autònoma de Barcelona
Splenic marginal zone B-cell lymphoma (SMZL) is a heterogeneous clinico-biological entity. The clinical course is variable, multiple genes are mutated with no unifying mechanism, and essential regulatory pathways and surrounding microenvironments are diverse. [...]
2022 - 10.1182/blood.2021012386
Blood, Vol. 139 Núm. 5 (february 2022) , p. 732-747  
2.
9 p, 698.5 KB Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib : A GIMEMA, ERIC and UK CLL FORUM study / Cuneo, Antonio (St. Anna University Hospital) ; Follows, George (Cambridge University Hospitals NHS Foundation Trust (Anglaterra)) ; Rigolin, Gian Matteo (St. Anna University Hospital) ; Piciocchi, Alfonso (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; Tedeschi, Alessandra (Niguarda Cancer Center) ; Trentin, Livio (University of Padua) ; Perez, Angeles Medina (Hospital Costa del Sol (Marbella)) ; Coscia, Marta (University of Turin) ; Laurenti, Luca (Policlinico A. Gemelli) ; Musuraca, Gerardo (Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST)) ; Farina, Lucia (Fondazione IRCCS Istituto Nazionale Tumori) ; Delgado, Alfredo Rivas (Hospital Clínic i Provincial de Barcelona) ; Orlandi, Ester Maria (Fondazione IRCCS Policlinico San Matteo) ; Galieni, Piero (Ospedale C. e G. Mazzoni) ; Mauro, Francesca Romana ("Sapienza" University) ; Visco, Carlo (San Bortolo Hospital) ; Amendola, Angela (San Carlo Hospital) ; Billio, Atto (Azienda Sanitaria dell'Alto Adige) ; Marasca, Roberto (University of Modena and Reggio Emilia) ; Chiarenza, Annalisa (Azienda Universitaria Ospedaliera Policlinico Vittorio Emanuele) ; Meneghini, Vittorio (University Hospital) ; Ilariucci, Fiorella (Arcispedale S. Maria Nuova) ; Marchetti, Monia (Cardinal Massaia Hospital) ; Molica, Stefano (Azienda Ospedaliera Pugliese Ciaccio) ; Re, Francesca (University Hospital) ; Gaidano, Gianluca (Università del Piemonte Orientale Amedeo Avogadro) ; Gonzalez, Marcos (Hospital Universitari IBSAL i CIBERONC) ; Forconi, Francesco (University Hospital National Health Service Trust) ; Ciolli, Stefania (Careggi Hospital) ; Cortelezzi, Agostino (University of Milan) ; Montillo, Marco (Niguarda Cancer Center) ; Smolej, Lukas (University Hospital) ; Schuh, Anna (Oxford University Hospitals NHS Foundation Trust) ; Eyre, Toby A. (Oxford University Hospitals NHS Foundation Trust) ; Kennedy, Ben (University Hospitals of Leicester NHS Trust) ; Bowles, Kris M. (Norwich Medical School) ; Vignetti, Marco (Italian Group for Adult Hematologic Diseases (GIMEMA)) ; De La Serna, Javier (Hospital 12 de Octubre (Madrid)) ; Moreno, Carol (Institut d'Investigació Biomèdica Sant Pau) ; Foà, Robin ("Sapienza" University) ; Ghia, Paolo (IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University) ; Universitat Autònoma de Barcelona
We performed an observational study on the efficacy of bendamustine and rituximab (BR) as first salvage regimen in chronic lymphocytic leukemia (CLL). In an intention-to-treat analysis including 237 patients, the median progression-free survival (PFS) was 25 months. [...]
2018 - 10.3324/haematol.2018.189837
Haematologica, Vol. 103 Núm. 7 (march 2018) , p. 1209-1217  
3.
13 p, 463.3 KB Targeting CD19 in diffuse large B-cell lymphoma : An expert opinion paper / Bailly, Sarah (Département d'Hématologie. Cliniques Universitaires Saint-Luc) ; Cartron, Guillaume (Centre Hospitalier Universitaire de Montpellier) ; Chaganti, Sridhar ; Cordoba, Raul (Hospital Universitario Fundación Jiménez Díaz) ; Corradini, Paolo (University of Milan) ; Düll, Johannes (Medizinische Klinik und Poliklinik II. Universitätsklinikum Würzburg) ; Ferrarini, Isacco (Department of Medicine. Section of Hematology. University of Verona) ; Osborne, Wendy (Newcastle Upon Tyne Hospitals NHS Foundation Trust) ; Rosenwald, Andreas (University of Würzburg) ; Sancho, Juan-Manuel (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ; Tilly, Hervé (Centre Henri Becquerel and University of Rouen) ; Van Den Neste, Eric (Cliniques Universitaires Saint-Luc) ; Viardot, Aandreas (University Hospital of Ulm (Alemanya)) ; Visco, Carlo (University of Verona) ; Universitat Autònoma de Barcelona
The ubiquitous, early-stage expression, efficient internalization, limited off-target effects, and high disease specificity of CD19 make it an attractive therapeutic target. Currently available anti-CD19 therapies have demonstrated particular promise in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. [...]
2022 - 10.1002/hon.3013
Hematological Oncology, Vol. 40 Núm. 4 (october 2022) , p. 505-517  

Vea también: autores con nombres similares
¿Le interesa recibir alertas sobre nuevos resultados de esta búsqueda?
Defina una alerta personal vía correo electrónico o subscríbase al canal RSS.